Cardiovascular Events in Individuals Treated With Sulfonylureas or Dipeptidyl Peptidase 4 Inhibitors
In this comparative effectiveness research study of sulfonylureas vs DPP4i in patients with T2D, the risk of MACE-4 events was highest for glipizide. These findings suggest that sulfonylureas, glipizide in particular, may not be the optimal agent in treatment of individuals with T2D at moderate cardiovascular risk.
Authors
- Marie E. McDonnell (ORCID: https://orcid.org/0000-0002-2263-9783)
- Vinit Nair
- Alan F. Kaul (ORCID: https://orcid.org/0000-0002-2501-6346)
- Vincent J. Willey (ORCID: https://orcid.org/0000-0002-6473-6469)
- Ryan M. Carnahan (ORCID: https://orcid.org/0000-0002-7478-4739)
- M. Cecilia Lansang (ORCID: https://orcid.org/0000-0002-7364-5550)
- Emma Hegermiller (ORCID: https://orcid.org/0000-0002-9835-491X)
- Andrea DeVries (ORCID: https://orcid.org/0000-0003-3656-8979)
- Lucia C. Petito (ORCID: https://orcid.org/0000-0002-0156-1219)
- Alexander Turchin (ORCID: https://orcid.org/0000-0002-8609-564X)
- Miguel A. Hernán (ORCID: https://orcid.org/0000-0003-1619-8456)
- Satyender Goel
- Elisa L. Priest (ORCID: https://orcid.org/0000-0003-0474-6275)
Institutions
- Northwestern University (US)
- University of Iowa (US)
- Brigham and Women's Hospital (US)
- University of Kentucky HealthCare (US)
- Cleveland Clinic (US)
- Harvard University (US)
- Wilmington University (US)
- Health Outcomes Solutions (United States) (US)
- Baylor Medical Center at Garland (US)
- Formedil (IT)
- LEK Consulting (United States) (US)
- Research Institute of Dallas (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.23067
- Citations
- 7
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 9.06